A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER

The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD on levodopa (L-DOPA) therapy (the double-blind period). The double-blind period will be followed by the open-label 52 week administration of pramipexole ER to evaluate the long term safety and efficacy (the open-label period).

Study Overview

• Status: Completed
• Conditions: Parkinson Disease
• Intervention / Treatment: Drug: Pramipexole Extended Release; Drug: Pramipexole Immediate Release

• Study Type: Interventional
• Enrollment (Actual): 112
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Japan
  • Akashi, Hyogo, Japan
    • 248.610.019 Boehringer Ingelheim Investigational Site
  • Akita, Akita, Japan
    • 248.610.020 Boehringer Ingelheim Investigational Site
  • Aomori, Aomori, Japan
    • 248.610.006 Boehringer Ingelheim Investigational Site
  • Asahikawa, Hokkaido, Japan
    • 248.610.017 Boehringer Ingelheim Investigational Site
  • Asahikawa, Hokkaido, Japan
    • 248.610.018 Boehringer Ingelheim Investigational Site
  • Bunkyo-ku, Tokyo, Japan
    • 248.610.001 Boehringer Ingelheim Investigational Site
  • Fuchu, Tokyo, Japan
    • 248.610.014 Boehringer Ingelheim Investigational Site
  • Fukuoka, Fukuoka, Japan
    • 248.610.011 Boehringer Ingelheim Investigational Site
  • Iwamizawa,Hokkaido, Japan
    • 248.610.015 Boehringer Ingelheim Investigational Site
  • Kodaira, Tokyo, Japan
    • 248.610.003 Boehringer Ingelheim Investigational Site
  • Kyoto, Kyoto, Japan
    • 248.610.008 Boehringer Ingelheim Investigational Site
  • Kyoto, Kyoto, Japan
    • 248.610.021 Boehringer Ingelheim Investigational Site
  • Morioka, Iwate, Japan
    • 248.610.010 Boehringer Ingelheim Investigational Site
  • Okayama, Okayama, Japan
    • 248.610.005 Boehringer Ingelheim Investigational Site
  • Osaka, Osaka, Japan
    • 248.610.012 Boehringer Ingelheim Investigational Site
  • Sagamihara, Kanagawa, Japan
    • 248.610.004 Boehringer Ingelheim Investigational Site
  • Shimogyo-ku, Kyoto, Kyoto, Japan
    • 248.610.009 Boehringer Ingelheim Investigational Site
  • Shiroishi, Miyagi, Japan
    • 248.610.007 Boehringer Ingelheim Investigational Site
  • Takamatsu, Kagawa, Japan
    • 248.610.002 Boehringer Ingelheim Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria

1. Male or female patients with diagnosis of PD including juvenile Parkinsonism, in whom the onset began at the age of forty or younger.
2. Patients with a modified Hoehn and Yahr scale of II to IV at "on" time.
3. Patients who have received an individual dosage of L-DOPA (either standard L-DOPA or L-DOPA with dopa-decarboxylase inhibitor) at a stable dose for at least 4 weeks before the baseline visit (Visit 2).

4. Patients who exhibit any therapeutically problematic issues or status based on L-DOPA therapy:

   • wearing-off phenomena
   • no on /delayed on
   • dystonia at off time
   • on-off phenomena
   • freezing phenomena at off time
   • the sub-optimal dose of L-DOPA had been administered due to side effects (such as dyskinesia), or therapeutical strategy

Exclusion criteria

1. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases.
2. Dementia, as defined by a Mini-Mental State Examination (MMSE) score <24 at screening visit.
3. Any psychiatric disorder according to DSM-IV criteria that could prevent compliance or completion of the trial and/or put the patient at risk if he/she takes part in the trial.
4. History of psychosis, except history of drug induced hallucinations (provided the investigator considers that participation in the trial would not represent a significant risk for the patient).
5. Clinically significant ECG abnormalities at screening visit, according to investigator's judgement.
6. Clinically significant hypotension or symptomatic orthostatic hypotension (i.e., clinical symptoms of orthostatic hypotension such as dizziness postural etc associated with a decline >=20 mmHg in systolic blood pressure and a decline >=10 mmHg in diastolic blood pressure, at one minute after standing compared with the previous supine systolic and diastolic blood pressure obtained after 5 minutes of quiet rest) either at screening visit or at baseline visit.
7. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the trial.
8. Pregnancy (to be excluded by serum pregnancy test at screening visit) or breast-feeding.
9. Sexually active female of childbearing potential not using a medically approved method of birth control within one month before to the screening visit and throughout the trial period.
10. Serum levels of AST, ALT, alkaline phosphatases or bilirubin >2 upper limits of normal .
11. Patients with a creatinine clearance <50 mL/min
12. Patients with a complication or signs of malignant tumours or those within 5 years after the treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pramipexole Extended Release; patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID	Drug: Pramipexole Extended Release; titration as individually needed (0.375 mg -4.5 mg daily)
Active Comparator: Pramipexole Immediate Release; patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID	Drug: Pramipexole Immediate Release; titrated as individually needed (0.25 mg - 4.5 mg daily)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Experienced Adverse Events	An adverse event is defined as any untoward medical occurrence	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score	UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms	baseline and after 12 weeks treatment
Change From Baseline in Percentage Off-time	Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).	baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia	Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia	Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia	Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 12 weeks treatment
Change From Baseline in Percentage On-time With Troublesome Dyskinesia	Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 12 weeks treatment
Responder Rate For Clinical Global Impression of Improvement (CGI-I)	CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)	baseline and after 12 weeks treatment
Responder Rate For Patient Global Impression of Improvement (PGI-I)	PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring of 1 or 2 (at least much better)	baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part I Score	UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood	baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part II Score	UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.	baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part III Score	UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms	baseline and after 12 weeks treatment
Change From Baseline in UPDRS Part IV Score	UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy	baseline and after 12 weeks treatment
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement)	Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse	baseline and after 12 weeks treatment
Change From Baseline in L-dopa Daily Dose	The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.	baseline and after 12 weeks treatment
Trough Plasma Concentration at Steady State	Geometric mean (gMean) was calculated for trough plasma concentrations of pramipexole at steady state after administration of pramipexole IR 4.5mg and pramipexole ER 4.5mg.	at Visit 8 after pramipexole ER 4.5mg and IR 4.5mg treatment
Dose Proportionality of Trough Plasma Concentration at Steady State After Pramipexole ER Treatment	Dose proportionality of trough plasma concentrations at steady state is explored by using the power model that described the functional relationship between the dose and plasma concentration	from Visit 1 to Visit 8 after pramipexole ER
Change From End of Double-Blind Period in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Dose Adjustment Phase)	UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms. Least square means and standard errors presented are from ANCOVA with factors treatment and covariate baseline.	Week 12 to Week 16
Percentage of Patients With no Worsening of UPDRS Parts II+III Total Score by More Than 15% From Week 12 to Week 16 (Open-label: Dose Adjustment Phase)	Percentage of patients with no worsening of UPDRS Parts II+III Total Score by more than 15% from week 12 to week 16 (Open-label: Dose Adjustment Phase)	Week 12 to Week 16
Clinical Global Impression of Improvement (CGI-I) at Week 16 Compared to Patient's CGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)	Clinical Global Impression of Improvement (CGI-I) at week 16 compared to patient's CGI-I status at week 12. CGI-I scores ranging from '1' (very much improved) to '7' (very much worse)	Week 12 to Week 16
Patient Global Impression of Improvement (PGI-I) at Week 16 Compared to Patient's PGI-I Status at Week 12 (Open-label: Dose Adjustment Phase)	Patient Global Impression of Improvement (PGI-I) at week 16 compared to patient's PGI-I status at week 12. PGI-I scores ranging from '1' (very much better) to '7' (very much worse).	Week 12 to Week 16
Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Parts II+III Total Score (Open-label: Maintenance Phase)	UPDRS II+III ranging from 0 point(normal) to 160 point (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms	Baseline and after 64 weeks treatment
UPDRS Parts II+III Total Score Responder Rate (at Least 20% Improvement) (Open-label: Maintenance Phase)	Responders are defined as at least 20% decrease in the UPDRS Parts II+III Total Score ranges 0-160 scores from best to worse	baseline and after 64 weeks treatment
Change From Baseline in Percentage Off-time (Open-label: Maintenance Phase)	Percentage off-time during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).	baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia (Open-label: Maintenance Phase)	Percentage on-time without dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia (Open-label Maintenance Phase)	Percentage on-time with non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0(worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time Without Dyskinesia or With Non-troublesome Dyskinesia (Open-label Maintenance Phase)	Percentage on-time without dyskinesia or non-troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 64 weeks treatment
Change From Baseline in Percentage On-time With Troublesome Dyskinesia (Open-label Maintenance Phase)	Percentage on-time with troublesome dyskinesia during waking hours in the last two days based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.	baseline and after 64 weeks treatment
Change From Baseline in L-dopa Daily Dose (Open-label Maintenance Phase)	The L-dopa daily dose was recorded in the electronic case report form (eCRF) at each trial visit.	baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part I Score (Open-label: Maintenance Phase)	UPDRS Part I ranging from 0 (normal) to 16 (severe). UPDRS Part I measures Mentation, Behavior and Mood	baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part II Score (Open-label: Maintenance Phase)	UPDRS Part II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS Part II at on and UPDRS Part II at off-period for each of the 13 activities.	baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part III Score (Open-label: Maintenance Phase)	UPDRS Part III ranging from 0 (normal) to 108 (severe). UPDRS Part III measures motor symptoms	baseline and after 64 weeks treatment
Change From Baseline in UPDRS Part IV Score (Open-label: Maintenance Phase)	UPDRS Part IV ranging from 0 (normal) to 23 (severe). UPDRS Part IV measures complications of therapy	baseline and after 64 weeks treatment

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info
• Related Info

Study record dates

Study Major Dates

• Study Start: November 1, 2007
• Primary Completion (Actual): November 1, 2009

Study Registration Dates

• First Submitted: November 16, 2007
• First Submitted That Met QC Criteria: November 16, 2007
• First Posted (Estimate): November 19, 2007

Study Record Updates

• Last Update Posted (Estimate): July 31, 2014
• Last Update Submitted That Met QC Criteria: July 29, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Protective Agents; Dopamine Agonists; Dopamine Agents; Antioxidants; Antiparkinson Agents; Anti-Dyskinesia Agents; Pramipexole
• Other Study ID Numbers: 248.610